This Stock Soared 12% After Its Blowout Earnings Outlook at the End of March, But It's Not Too Late to Buy

Chewy guided 2026 revenue growth to a midpoint of 8.5% (vs 8.3% in 2025) and expects EBITDA margins to expand from 5.7% to 6.6–6.8% this year, with a long-term target above 10%. Management cited execution on initiatives — 10 new Vet Care clinics (total 18), expanded private-label brands (Get Real, Chewy Made), and autoship penetration rising to ~84% of Q4 net sales — driving margin and loyalty improvements. Shares jumped ~12% on the outlook, while the stock trades at an aggregate ~12x EV/EBITDA despite implied EBITDA growth of ~25–30% this year.

Analysis

Chewy’s moves (vet clinics, private-label expansion, and ad monetization) shift value capture away from branded suppliers and passive retail distribution toward an owned, recurring-revenue model. Second-order effects: branded CPGs will face margin pressure and may push back via trade promotions or exclusive SKUs, increasing working capital for Chewy as suppliers demand slotting or marketing support. Independently owned veterinary groups and specialty pharmacists become strategic adversaries — expect local regulatory and supplier lobbying as Chewy scales clinical services.

Margin expansion is credible but lumpy; advertising and private-label are high-leverage but can reverse quickly if CPMs fall or private-label unit economics hit quality/frequency limits. Autoship-like loyalty programs have steep early returns but show declining marginal lift once penetration passes mid-teens of addressable customers; anticipate a visible slowdown in incremental LTV within 12–24 months unless Chewy finds new retention levers. Macro/operational tail risks (input cost inflation, freight dislocations, or regulatory constraints around prescriptions/clinic ownership) could compress EBITDA by several hundred basis points in a downside scenario.

That creates a favorable asymmetric payoff: the market may be underpricing sustained margin improvement tied to clinic-driven prescription capture and higher-margin owned SKUs, while overstating permanence of ad growth. Trade implementation should focus on capturing the execution optionality while limiting exposure to an ad/cycle reversion or regulatory shock. Key near-term catalysts to watch are sequential ads RPMs, private-label gross margin trends by quarter, and the pace of clinic openings combined with prescription fill rates.

Key Decisions for Investors

• Core idea — Long CHWY (size 1–2% NAV): initiate on a pullback of ~8–12% or on evidence of sequential private-label margin improvement (2–3 quarters). Target 50–80% upside over 12–24 months if clinic/prescription capture and private-label scale materialize; hard stop at -30% to limit single-name risk.
• Pair trade — Long CHWY / Short WOOF (equal dollar, net neutral market beta): 6–18 month horizon to isolate execution/monetization vs. retail service peers. Expect 25–40% relative outperformance if CHWY converts clinic -> pharmacy revenue and scales owned SKUs; downside if both retail channels weaken together, so cap exposure to 0.5–1% NAV each.
• Options implementation — Buy 12–18 month CHWY call spread (buy LEAP call, sell a higher-strike near-dated call) to create a funded long with ~3:1 upside/downside leverage. Use this to express conviction while limiting max loss to premium paid (target: premium = 2–4% of intended equity exposure).
• Tail hedge — Buy 9–12 month CHWY put spread 20–30% OTM sized at 10–20% of core position to protect vs regulatory or ad-revenue shock. Cost should be <1% NAV; preserves asymmetric upside while capping idiosyncratic blow-ups.